SCHEMBL829614

SCHEMBL829614

Cc1ccc(OC(=O)N2CCC(C)CC2)c(Br)c1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.55
KDM4E B2RXH2 2/20 0.55
HTT P42858 1/20 0.55
GAA P10253 2/20 0.52
SMN1; SMN2 Q16637 2/20 0.48
TSHR P16473 2/20 0.48
HPGD P15428 2/20 0.48
NPC1 O15118 1/20 0.48
RAB9A P51151 1/20 0.48
KMT2A Q03164 3/20 0.47
POLB P06746 2/20 0.45
MCOLN3 Q8TDD5 1/20 0.45
MAPK1 P28482 1/20 0.43
ABL1 P00519 1/20 0.42
RIN1 Q13671 1/20 0.42
MEN1 O00255 2/20 0.42
TP53 P04637 1/20 0.42
PKM P14618 1/20 0.41
CYP1A2 P05177 1/20 0.41
CYP3A4 P08684 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL830130 0.86 SMN1; SMN2 (0.63) ALDH1A1KDM4EHTTGAASMN1; SMN2
SCHEMBL830404 0.84 SMN1; SMN2 (0.45) ALDH1A1KDM4EHTTGAASMN1; SMN2
SCHEMBL829640 0.82 GAA (0.64) ALDH1A1KDM4EHTTGAASMN1; SMN2
SCHEMBL829584 0.81 FAAH (0.53) ALDH1A1KDM4EKMT2AMEN1CYP2C9
SCHEMBL8844812 0.80 GAA (0.62) ALDH1A1HTTGAASMN1; SMN2NPC1
SCHEMBL830050 0.79 SMN1; SMN2 (0.60) ALDH1A1KDM4EHTTGAASMN1; SMN2
SCHEMBL830113 0.78 TSHR (0.45) ALDH1A1KDM4EHTTGAASMN1; SMN2
SCHEMBL829010 0.78 GAA (0.48) ALDH1A1KDM4EHTTGAASMN1; SMN2
SCHEMBL10458999 0.77 GAA (0.74) ALDH1A1HTTGAASMN1; SMN2HPGD
SCHEMBL8844984 0.73 GAA (0.68) ALDH1A1HTTGAASMN1; SMN2HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8143257-B2 inhibiting angiogenesis; cancer, diabetic retinopathy, rheumatoid arthritis, psoriasis, atherosclerosis, obesity, chronic inflammation or exudative macular degeneration; 4-(Hydroxy-diphenyl-methyl)-piperidine-1-carboxylic acid 1-bromo-naphthalen-2-yl ester PTC THERAPEUTICS, INC. (US) 2012-03-27 US disclosed
US-8143257-B2 inhibiting angiogenesis; cancer, diabetic retinopathy, rheumatoid arthritis, psoriasis, atherosclerosis, obesity, chronic inflammation or exudative macular degeneration; 4-(Hydroxy-diphenyl-methyl)-piperidine-1-carboxylic acid 1-bromo-naphthalen-2-yl ester PTC THERAPEUTICS, INC. (US) 2012-03-27 US disclosed
US-8143257-B2 inhibiting angiogenesis; cancer, diabetic retinopathy, rheumatoid arthritis, psoriasis, atherosclerosis, obesity, chronic inflammation or exudative macular degeneration; 4-(Hydroxy-diphenyl-methyl)-piperidine-1-carboxylic acid 1-bromo-naphthalen-2-yl ester PTC THERAPEUTICS, INC. (US) 2012-03-27 US disclosed
US-20080261956-A1 Substituted Phenols as Active Agents Inhibiting Vegf Production PTC THERAPEUTICS, INC. 2008-10-23 US disclosed
US-20080261956-A1 Substituted Phenols as Active Agents Inhibiting Vegf Production PTC THERAPEUTICS, INC. 2008-10-23 US disclosed
US-20080261956-A1 Substituted Phenols as Active Agents Inhibiting Vegf Production PTC THERAPEUTICS, INC. 2008-10-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080261956-A1 Substituted Phenols as Active Agents Inhibiting Vegf Production VEGFA, FLT4, FLT1 ALDH1A1 936/4885KDM4E 358/4885HTT 2505/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.